Psilocybin for Treatment-Resistant Suicidal Ideation: What a New Trial Shows

Suicidal thinking is one of the hardest experiences to treat, and one of the most common reasons people reach a treatment center. For some people it lifts with therapy and time. For others it becomes chronic — present more days than not, for months or years, surviving multiple rounds of medication. That group has the fewest good options, and a study published this month adds a measured note of hope.

In the May 2026 issue of The Journal of Clinical Psychiatry, researchers at Sheppard Pratt in Baltimore reported the first prospective trial of psilocybin-assisted therapy aimed specifically at chronic, treatment-resistant suicidal ideation. The results are striking. They are also early, and worth reading carefully before drawing conclusions.

If you are having thoughts of suicide right now, this article is not the help you need in this moment. Call or text 988 (the Suicide & Crisis Lifeline), or go to your nearest emergency room. Psilocybin is not a crisis treatment, and nothing below is a substitute for immediate support.

Can psilocybin reduce suicidal ideation?

In this trial, yes — meaningfully, and faster than most treatments. A single supervised dose of psilocybin, surrounded by therapy, was associated with large reductions in suicidal ideation that held for three months. But “associated with” is doing real work in that sentence. This was an open-label study with no placebo group, so it cannot yet prove that psilocybin itself caused the change. What it offers is a strong early signal that deserves a controlled trial — not a finished answer.

What the new trial found

The study followed 20 adults, all of whom carried a diagnosis of major depressive disorder, all of whom had active suicidal thoughts more days than not for at least three months, and all of whom had already failed at least two adequate antidepressant trials. In other words, this was the hard-to-treat group — the people for whom the standard playbook had already been run.

Each participant received a single 25-mg oral dose of psilocybin. Crucially, the dose was not the whole intervention. Participants first tapered off other psychiatric medications, then completed three preparation sessions — more than six hours of therapy — before the roughly eight-hour dosing session itself, which took place with two therapists present. Three integration sessions followed. The psilocybin was the centerpiece, but it sat inside a structured course of psychological support.

The outcomes, measured on the Modified Scale for Suicidal Ideation:

• By week 3, suicidal ideation scores had dropped sharply (mean difference 13.95; P < .001), and 15 of 20 participants — 75% — had at least a 50% reduction in ideation.
• By week 12, 70% of participants (14 of 20) had minimal or no suicidal ideation, and 7 of 20 had reached full remission, scoring zero.
• Depression scores fell in parallel, and the two improvements tracked each other closely.

The effect sizes the authors reported (Cohen’s d between roughly 1.5 and 2.1) are, in their words, “among the largest reported for any psychiatric intervention for this condition” — followed immediately by the caution that “these uncontrolled estimates must be interpreted with caution.” That pairing of optimism and restraint is the right way to read the whole study.

On safety, the trial was reassuring within its small size: no serious adverse events, and no one dropped out. Side effects were transient and mild to moderate. One participant with co-occurring PTSD had a panic attack during dosing that required medication. And two of the twenty saw their suicidal ideation increase relative to baseline — one transiently, one in a way the researchers considered clinically significant at week 12. In a study of 20 people, that is not a footnote. It is a reminder that this is a serious medical intervention with real risk, not a wellness trend.

Why “treatment-resistant” is the key phrase

It would be easy to read a headline about psilocybin and suicidal ideation and picture it as a first move. It is not. Every person in this trial had already tried and not responded to conventional treatment. That framing matters for two reasons.

First, it is the group with the greatest unmet need. When two or more antidepressants have failed and suicidal thoughts have become a daily background hum, the realistic options narrow considerably. A treatment that produces rapid change in exactly that population is genuinely important.

Second, it tells you where psilocybin might fit — and where it doesn’t. This is not evidence that someone newly struggling should skip therapy and standard care. It is evidence that, for people who have run that course without relief, a supervised psilocybin experience may be worth studying as a next step.

How this fits alongside DBT

At FRTC, the treatment we lean on most heavily for suicidal behavior is dialectical behavior therapy. DBT was built, by Marsha Linehan, specifically for chronically suicidal people, and it carries decades of randomized controlled trials showing it roughly halves suicide attempts and self-harm. That evidence base is far deeper than anything psilocybin has yet — and it is not in competition with these new findings.

If anything, the trial underlines what DBT clinicians already believe: the medicine is not the whole story. The psilocybin dose worked inside a frame of preparation, support, and integration. That is the same logic behind DBT for self-harm and suicidality — skills, practice, and a relationship that helps a person carry change out of the office and into a hard week. The most honest way to think about natural medicine right now is as a possible adjunct to that ongoing work, not a replacement for it. A single profound experience can open a door. Skills are what let someone walk through it and stay.

One accuracy note worth making plainly: this trial enrolled people with major depressive disorder, not borderline personality disorder. Suicidal ideation is central to BPD too, and it is reasonable to be curious whether psilocybin could help there — but no one should treat this study as evidence about BPD. That research has not been done.

The limitations that matter

The researchers were candid about the study’s boundaries, and so should anyone citing it be:

• No control group. Without a placebo comparison, expectancy and the intensive therapy surrounding the dose cannot be separated from the drug. Open-label psychedelic studies are known to produce inflated effects.
• Only 20 people, at one specialized center. That is too small to detect rare harms and too narrow to generalize to ordinary clinical settings.
• Durability is genuinely unclear. More than half the participants restarted psychiatric medication after week 3, which makes the three-month results harder to attribute cleanly to the psilocybin.
• Industry funding. The study was funded by Compass Pathways, the company developing the synthetic psilocybin used, and several authors disclosed financial ties to it. The funder reportedly had no role in the analysis, but the context belongs in any honest summary.

None of this erases the result. It frames it. This is a well-designed pilot pointing toward a larger, controlled trial — the necessary next step before psilocybin can be called a treatment for suicidal ideation rather than a promising candidate.

What this means if you’re in Colorado

Colorado is one of the few places where this question is not purely academic. Under the Natural Medicine Health Act, supervised psilocybin services are now legally available through licensed facilitators and healing centers. FRTC offers natural medicine services within that framework.

But the trial above should shape expectations more than it raises them. Supervised psilocybin is not crisis care, not a prescription you pick up, and not appropriate for anyone in an acute suicidal episode — the study itself excluded people with active intent. It is a considered step, taken with clinical support, ideally alongside ongoing therapy, for people who have already worked hard at recovery without enough relief.

If chronic suicidal thinking is part of your life, the most useful next move is rarely a single decision about one treatment. It is a conversation with clinicians who can look at the whole picture — what you’ve tried, what’s still on the table, and whether something like natural medicine has a sensible place in it. If that’s where you are, you can reach our team for a free consultation.

This article discusses suicide and is intended as general education, not medical advice. If you or someone you know is struggling, call or text 988 in the U.S. to reach the Suicide & Crisis Lifeline.